Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia

Aberrant signaling triggered by oncogenic or hyperactive RAS proteins contributes to the malignant phenotypes in a significant percentage of myeloid malignancies. Of these, juvenile myelomonocytic leukemia (JMML), an aggressive childhood cancer, is largely driven by mutations in RAS genes and those...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Baker, Stacey J., Cosenza, Stephen C., Ramana Reddy, M.V., Premkumar Reddy, E.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2019
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6443005/
https://ncbi.nlm.nih.gov/pubmed/30956775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26735
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares